Hi
@chrisauGreat article you posted there mate, thanks.
There is one thing specifically in that presentation that struck me.
Recce is also permitted to supply RECCE 327 to Australian medical practitioners for seriously ill patients for whom death is reasonably likely to occur within a matter of months or in the absence of early treatment, under the Australian Therapeutic Goods Administration (TGA) Special Access Scheme Category A.This being the case, I do not deny the validity of the statement as it comes from someone within RECCE. Recce executive director of regulatory affairs Michele Dilizia.
So why are we not using this loophole in the system to use RECCE 327 on someone, or a group of patients that are willing and are terminally ill from Covid. This is the way in quickly from my perspective.
Ladies and Gents, WE NEED TO MAKE A NOISE.
RED
(20min delay)